We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.005 | 0.02% | 28.575 | 28.54 | 28.575 | 29.085 | 28.49 | 28.875 | 168,753 | 17:26:27 |
From May 2021 to May 2024
By Colin Kellaher
Bayer AG on Tuesday said it is advancing a pair of therapies targeting the neurodegenerative movement disorder Parkinson's disease.
The German company said its BlueRock Therapeutics unit has administered the first dose of its investigational pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson's disease patient in an open-label Phase 1 clinical safety and tolerability study.
In a parallel gene-therapy program, Bayer's Asklepios BioPharmaceutical Inc. unit is recruiting and evaluating patients in a Phase 1b study to assess safety and preliminary efficacy.
Bayer said there is currently no disease-modifying treatment available for Parkinson's disease, which affects more than 10 million people around the world.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 08, 2021 07:51 ET (11:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
